Although epithelial dysplasia is the gold standard for assessing the risk of oral malignant transformation, podoplanin and adenosine triphosphate (ATP)-binding cassette G2 subfamily protein expression in patients with OLP may be used as biomarkers for risk evaluation. This evidence concerns the gene PDPN and oral lichen planus.